BioInvent International AB (publ) (BINV) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, and welcome, everybody, to our year-end report. Today is February 26, 2026. And as usual, I will start with the summary. So we had a couple of key events in the fourth quarter. First of all, the two ASH data sets. So with BI-1808, our lead candidate targeting TNF receptor 2, we saw very strong data in the T cell lymphoma. And we presented that at ASH 2025, and I'll come back to the data a little bit more in detail later. And then we had another ASH presentation about BI1206, which is our lead targeting FZGAMR2B in combination with rituximab and calquence in non-Hodgkin's lymphoma. And that was also presented at ASH 2025 and also very, very strong data set. I should mention that BI-1808, that was monotherapy, single agent therapy. Then we also started our phase 2A trial evaluating BR1206 in combination with Pembrolizumab in treatment naive advanced or metastatic non-small cell lung cancer and uveal melanoma. So this is really the first line setting. And this is, as I will explain later, based on data that we have seen in end-of-the-line patients and the data actually convinced Merck to go together with us into first line under a supply and collaboration agreement. And then last but not least, we also got orphan drug designation from EMA for BR1808, another very important milestone for the treatment of cutaneous T-cell lymphoma, CTCL. And then we had a couple of events after the end of the period. Number one, obviously, a very promising data set in our ongoing phase 2A study for BR1808 with Keytruda for the treatment of recurrent ovarian cancer. And we published that ahead of JP Morgan. And I will also discuss that data set a little bit more in detail. And then we had here in the report, and maybe not everybody is aware about this, but I will highlight it, u...